SAN
FRANCISCO, Dec. 26, 2024 /PRNewswire/ -- AusperBio
Therapeutics, Inc. and Ausper Biopharma Co., Ltd.
(collectively AusperBio), a privately held clinical-stage
biotechnology company dedicated to advancing targeted
oligonucleotide therapies to achieve a functional cure for chronic
hepatitis B (CHB), today announced the successful completion
of a USD 73 million Series B
financing.
The round was led by HanKang Capital, with participation
from Sherpa Capital, CDH Investments, and a strategic
investor, as well as continued participation from existing
investors Qiming Venture Partners, InnoPinnacle Fund,
and YuanBio Venture Capital. This financing followed the
company's Series A round completed in July this year, demonstrating
continued investor confidence in its proprietary platform and
strategic direction.
The proceeds will fund the continued Phase 2 development of
AHB-137, AusperBio's lead investigational therapy,
supporting both clinical studies in China and global trials, as well as the
development of commercial-scale manufacturing processes. The
funding will also facilitate the expansion of the company's
therapeutic pipeline and operational capabilities to drive
sustained growth.
Dr. Guofeng Cheng,
co-founder and CEO of AusperBio, stated, " We are honored
by our investors' confidence and support. This milestone financing
recognizes our scientific and clinical accomplishments to date and
enables us to accelerate our clinical programs and move closer to
delivering a functional cure for CHB patients in need."
Dr. Chris Yang, co-founder
and CSO, added, "AHB-137 continues to attract attention from the
scientific and clinical communities, particularly after the
late-breaking oral presentation at the recent AASLD conference. The
promising clinical data further validates our Med-Oligo™
platform, strengthening our development of groundbreaking targeted
oligonucleotide therapies for CHB and other serious chronic
diseases."
AusperBio is committed to delivering patient-centered
innovations, aiming to alleviate the global health burden of CHB
and transform treatment paradigms for this serious chronic
disease.
About AHB-137
AHB-137, a novel unconjugated antisense oligonucleotide
(ASO) developed within AusperBio's proprietary Med-Oligo™
ASO technology platform, was designed to treat chronic
hepatitis B for a functional cure. Its compelling preclinical and
Phase 1 clinical data were highlighted at the 2023 EASL
conference and the 2024 EASL conference, respectively.
Interim Phase 2a data was presented in a late-breaking oral session
at the 2024 AASLD. This novel dual-mechanism ASO has
completed its global Phase 1b trial
and is now undergoing multiple Phase 2 trials in China. With its global development
strategy, AHB-137 is advancing rapidly toward the goal of
an HBV cure.
About AusperBio.
AusperBio is a clinical-stage biopharmaceutical company with
operations in the USA and China, dedicated to advancing oligonucleotide
and targeted delivery technologies for transformative therapies,
with an initial focus on curing chronic hepatitis B infection. The
company has developed a proprietary Med-Oligo™ ASO
platform which has been shown to substantially enhance the current
ASO therapeutics, through novel insights into ASO design. Combining
with efficient targeted delivery conjugation technologies, the
modular Med-Oligo™ Platform empowers ASO therapeutics
to treat a broad range of diseases, including viral infections,
metabolic conditions, genetic disorders, and immune diseases.
For further information, please contact:
Media
Contact
Email: info@ausperbio.com
Investor Relations Contact:
Tel: 650-888-1756 (US)
Email: growth@ausperbio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ausperbio-secures-73-million-in-series-b-financing-to-advance-functional-cure-for-chronic-hepatitis-b-302339451.html
SOURCE AusperBio Therapeutics Inc.
